Can One Year DM1 Data Change The Bull Case For Dyne Therapeutics Stock?

Simply Wall St.

3 hours ago

Dyne Therapeutics reported additional one year data from the Phase 1/2 ACHIEVE trial of z basivarsen in DM1, with sustained improvements across myotonia, function, strength and patient reported ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://nz.tigrwd.com/news/2675351731"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2675351731\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2675351731?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-10-13 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2675351731","market":"hk","top_or_hot":-1,"title":"Can One Year DM1 Data Change The Bull Case For Dyne Therapeutics Stock?","media":"Simply Wall St.","content":"<div>\n<p>Dyne Therapeutics reported additional one year data from the Phase 1/2 ACHIEVE trial of z basivarsen in DM1, with sustained improvements across myotonia, function, strength and patient reported ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dyn/dyne-therapeutics/news/can-one-year-dm1-data-change-the-bull-case-for-dyne-therapeu\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can One Year DM1 Data Change The Bull Case For Dyne Therapeutics Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan One Year DM1 Data Change The Bull Case For Dyne Therapeutics Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-13 19:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dyn/dyne-therapeutics/news/can-one-year-dm1-data-change-the-bull-case-for-dyne-therapeu><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dyne Therapeutics reported additional one year data from the Phase 1/2 ACHIEVE trial of z basivarsen in DM1, with sustained improvements across myotonia, function, strength and patient reported ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dyn/dyne-therapeutics/news/can-one-year-dm1-data-change-the-bull-case-for-dyne-therapeu\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VOTE","symbol_name":"TCW Transform 500 ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dyn/dyne-therapeutics/news/can-one-year-dm1-data-change-the-bull-case-for-dyne-therapeu","article_id":"2675351731","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dyn/dyne-therapeutics/news/can-one-year-dm1-data-change-the-bull-case-for-dyne-therapeu","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2675351731","pubTimestamp":1791890911,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Dyne Therapeutics reported additional one year data from the Phase 1/2 ACHIEVE trial of z basivarsen in DM1, with sustained improvements across myotonia, function, strength and patient reported outcomes, along with a favorable safety profile compared with natural history cohorts.\nThe mixed dose exposures in the pooled group and the alignment of key ACHIEVE and HARMONIA endpoints with potential accelerated and traditional approvals provide investors with clearer insight into how Dyne...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"VOTE":"TCW Transform 500 ETF","JOYT":"JPMorgan Equity and Options Total Return ETF","FEBU":"AllianzIM U.S. Equity Buffer15 Uncapped Feb ETF","RGLO":"Global Equity Active ETF","BK4588":"碎股","DYN":"戴纳基","PMDE":"PGIM S&P 500 Max Buffer ETF - December","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","DECU":"AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF","GXDW":"Global X Dorsey Wright Thematic ETF","BK4139":"生物科技","VGFPF":"Vanguard Funds PLC"},"translate_title":"一年的 DM1 数据能否改变达因治疗股票的牛市情况？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DYN":1.5,"VOTE":0.65,"PMDE":0.65,"RGLO":0.65,"JOYT":0.65,"VGFPF":0.65,"DECU":0.65,"FEBU":0.65,"GXDW":0.65},"content_text":"Dyne Therapeutics reported additional one year data from the Phase 1/2 ACHIEVE trial of z basivarsen in DM1, with sustained improvements across myotonia, function, strength and patient reported outcomes, along with a favorable safety profile compared with natural history cohorts. The mixed dose exposures in the pooled group and the alignment of key ACHIEVE and HARMONIA endpoints with potential accelerated and traditional approvals provide investors with clearer insight into how Dyne Therapeutics is designing a path from early clinical signals toward potential long term commercial use in DM1. We will now examine how Dyne Therapeutics' investment narrative could be influenced by sustained one year functional gains in DM1.  Spot 20 high quality undiscovered gems pursuing similarly ambitious treatments, so you can compare Dyne Therapeutics' DM1 story with other under the radar healthcare opportunities.\nAdvertisementDyne Therapeutics Investment Narrative Recap To own Dyne Therapeutics, you need to believe this is a rare disease platform that can turn the recent DM1 signal, the DMD franchise and a broad FORCE pipeline into approved products while managing heavy R&D and no current revenue. The new one year ACHIEVE data supports that thesis but does not remove the binary nature of upcoming readouts. The key near term catalyst still sits with ACHIEVE REC vHOT data in early 2027 and the HARMONIA 5xSTS outcome that follows. The biggest risk remains that z basivarsen fails to show a persuasive effect on those registrational endpoints, which could leave Dyne Therapeutics with high spend, shareholder dilution and a longer road to meaningful sales. The clearest link between this update and the catalyst stack is the accepted BLA with Priority Review for z rostudirsen in exon 51 DMD, which carries a January 21, 2027 PDUFA date. That filing shows Dyne Therapeutics already interacting with regulators on another FORCE asset while z basivarsen advances, creating parallel shots on goal. If z rostudirsen reaches the market and the broader DMD exon skipping portfolio expands as planned, any DM1 approval would slot into an existing commercial footprint instead of requiring a fresh build out. That operational overlap, combined with the recent equity raise and cash plus term loan capacity, gives the group time to execute but also extends exposure to regulatory and execution risk. What The Dyne Therapeutics Forecasts Really Assume Dyne Therapeutics' long term story is tied directly to some punchy analyst math. Forecasts point to revenue of US$472.1 million by 2029, off a base of zero today. That profile reflects a shift from pure R&D vehicle to fully commercial business if the pipeline clears regulatory hurdles. Profit expectations embed an equally sharp turn. Analysts map earnings moving from a loss of US$519.4 million today to a profit of US$81.4 million in 2029, using a 17.2% profit margin that matches the current average for US biotech peers. That swing of US$600.8 million in earnings is what underpins the use of a 126.3x future P/E multiple on those projected 2029 profits. The valuation overlay is demanding. To line up with the US$36.0 analyst target, investors would have to accept Dyne Therapeutics at that 126.3x P/E on 2029 earnings, which is above the 17.1x P/E cited for the broader US biotech group. The gap between those multiples illustrates how much success in DM1 and DMD is already embedded in the long range numbers. Share count assumptions matter as well. Consensus figures build in 7.0% yearly growth in shares outstanding over the next three years, reflecting ongoing capital needs as late stage studies, regulatory work and commercial build out progress. Any additional equity raises beyond that could dilute per share earnings relative to the headline profit estimate. Dyne Therapeutics' narrative projects US$472.1 million in revenue and US$81.4 million in earnings by 2029. This implies very rapid yearly revenue growth from zero today and a US$600.8 million earnings increase from a loss of US$519.4 million. Discover why Dyne Therapeutics' fair value suggests a 126% potential upside to its current price, which could narrow quickly. NasdaqGS:DYN 1-Year Stock Price Chart Exploring Other Perspectives One alternate story around Dyne Therapeutics leans hard into DM1 risk. The most bearish analysts were only penciling in about US$222.0 million of 2029 revenue and US$38.2 million of earnings before this new one year ACHIEVE update. That is a much more cautious path. Use it as a reference point while you compare different views. Explore 4 other Dyne Therapeutics fair value estimates, including one that suggests it could be worth just $16.12. Reach Your Own Conclusion Don't just follow the ticker; dig into the data and build a conviction that's truly your own.  A great starting point for your Dyne Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision. See our latest analysis for Dyne Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Dyne Therapeutics' overall financial health at a glance.  Looking For More Investment Ideas Beyond Dyne Therapeutics? If Dyne Therapeutics has sharpened your interest in high conviction stories, consider broadening your watchlist with a few targeted stock lists that match different risk and income preferences.  For investors who want income as a core part of the thesis, review 8 dividend fortresses to help focus on companies that prioritize cash returns to shareholders. If capital protection and steadier profiles matter more to you than rapid upside, filter for 31 resilient stocks with low risk scores to help anchor a more defensive section of your portfolio. When you want strong finances as a foundation before you even think about growth, start with a list of solid balance sheet and fundamentals (25 results) to help you zero in on businesses with room to fund their plans.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}